Pierluigi Antonelli was less than three months into his role as a member of the Management Board of Fresenius, responsible for the group’s operating company Fresenius Kabi, when he recognised an eye
The six biosimilars to Johnson & Johnson ’s Stelara that have launched in the US have list prices 80% to 90% below the innovator’s wholesale acquisition cost, representing deeper discounts than t
The six biosimilars to Johnson & Johnson ’s Stelara that have launched in the US have list prices 80% to 90% below the innovator’s wholesale acquisition cost, representing deeper discounts than t
Fresenius Kabi has become the latest company to settle litigation with Amgen over biosimilar denosumab, with the German company disclosing to Generics Bulletin details of resultant launch dates for